HanefeldM, KoehlerC, HoffmannC, WilhelmK, KamkeW, GersteinH. Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early type 2 diabetes. Diabet Med, 2010; 27:175–180.
2.
BorgR, KuenenJC, CarstensenB, ZhengH, NathanDM, HeineRJ, NerupJ, Borch-JohnsenK, WitteDR. ADAG Study Group: HbA1c and mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycaemia or glucose variability in persons with diabetes: the A1C-Derived Average Glucose (ADAG) study. Diabetologia, 2011; 54:69–72.
3.
MuggeoM, ZoppiniG, BonoraE, BrunE, BonadonnaRC, MoghettiP, VerlatoG. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care, 2000; 23:45–50.
4.
TakaoT, IdeT, YanagisawaH, KikuchiM, KawazuS, MatsuyamaY. The effect of fasting plasma glucose variability on the risk of retinopathy in type 2 diabetic patients: retrospective long-term follow-up. Diabetes Res Clin Pract, 2010; 89:296–302.
5.
International Diabetes Federation. Self-Monitoring of Blood Glucose in Non-Insulin-Treated Type 2 Diabetes. Brussels: International Diabetes Federation, 2009.
6.
PolonskyWH, FisherL, SchikmanCH, HinnenDA, ParkinCG, JelsovskyZ, PetersenB, SchweitzerM, WagnerRS. Structured self-monitoring of blood glucose significantly reduces A1c levels in poorly controlled, noninsulin-treated type 2 diabetes—results from the Structured Testing Program Study. Diabetes Care, 2011; 34:262–267.
7.
McManusRJ, MantJ, BrayEP, HolderR, JonesMI, GreenfieldS, KaambwaB, BantingM, BryanS, LittleP, WilliamsB, HobbsFD. Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial. Lancet, 2010; 376:163–172.
8.
Hoffmann-La Roche. PRISMA Study (Prospective, Randomized Trial on Intensive Self-Monitoring Blood Glucose Management Added Value in Non-Insulin Treated Type 2 Diabetes Mellitus Patients)NCT00643474.March15, 2011ClinicalTrials.gov2011 May 23.
9.
American Association of Diabetes Educators: Diabetes Education Fact Sheet. www.diabeteseducator.org/export/sites/aade/_resources/pdf/research/Diabetes_Education_Fact_Sheet_09-10.pdf. 2011 August 15.
AbuDaggaA, ResnickHE, AlwanM. Impact of blood pressure telemonitoring on hypertension outcomes: a literature review. Telemed J E Health, 2010; 16:830–838.
12.
PolisenaJ, TranK, CimonK, HuttonB, McGillS, PalmerK. Home telehealth for diabetes management: a systematic review and meta-analysis. Diabetes Obes Metab, 2009; 11:913–930.
13.
LeichterSB, AdkinsRA, BowmanKL. Telemedical management of diabetic patients by computer versus traditional care: a controlled clinical trial [late breaking poster]Presented at General Poster Session II, American Diabetes Association. 71st Scientific Sessions: San Diego, CA, 2011.
14.
YaffeK, BlackwellT, MS, KanayaAM, DavidowitzN, Barrett-ConnorE, KruegerK. Diabetes, impaired fasting glucose and development of cognitive impairment in older women. Neurology, 2004; 63:658–663.
15.
YaffeK, BlackwellT, WhitmerRA, KruegerK, Barrett ConnorE. Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. J Nutr Health Ageing, 2006; 10:293–295.
16.
TraykovL, BollerF. Frontal lobes pathology, dementia. An appraisal of the contribution of Leonardo Bianchi. Ital J Neurol Sci, 1997; 18:129–134.
17.
BollerF, TraykovL, Dao-CastellanaMH, Fontaine-DabernardA, ZilboviciusM, RancurelG, PappataS, SamsonY. Cognitive functioning in “diffuse” pathology. Role of prefrontal and limbic structures. Ann N Y Acad Sci, 1995; 769:23–39.
18.
SeguraB, JuradoMA, FreixenetN, FalcónC, JunquéC, ArboixA. Microstructural white matter changes in metabolic syndrome. A diffusion tensor imaging study. Neurology, 2009; 73:438–444.
19.
ProchaskaJO, DiClementeCC. The transtheoretical approach. NorcrossJC, GoldfriedMR. Handbook of Psychotherapy Integration, 2nd. New York: Oxford University Press, 2005; 147–171.
20.
LeventhalH, MeyerD, NerenzD. The common sense representation of illness danger. RachmanS. Medical Psychology, II. New York: Pergamon Press, 1980; 7–30.
21.
BanduraA. Social Foundations of Thought Action: A Social Cognitive Theory. Englewood Cliffs, NJ: Prentice-Hall, 1986.
22.
SkinnerTC, van der VenN. Psychological group interventions in diabetes care. SnoekF, SkinnerC. Psychology in Diabetes Care. Chichester, UK: John Wiley & Sons Ltd., 2004; 141–169.
23.
AndersonRM. Patient empowerment and the traditional medical model: a case of irreconcilable differences?Diabetes Care, 1995; 18:412–425.
24.
HolmanH, LorigK. Patients as partners in managing chronic disease. BMJ, 2000; 320:526–527.
25.
PlackK, HerpertzS, PetrakF. Behavioural medicine interventions in diabetes. Curr Opin Psychiatry, 2010; 23:131–138.
26.
PeyrotM, RubinRR. Behavioral and psychosocial interventions in diabetes. Diabetes Care, 2007; 30:2433–2440.
27.
CramerJA, PughMJ. The influence of insulin usage on glycemic control: how well do adults follow prescriptions for insulin?Diabetes Care, 2005; 28:78–83.
28.
PoundP, BrittenN, MorganM, YardleyL, PopeC, Daker-WhiteG, CampbellR. Resisting medicines: a synthesis of qualitative studies of medicine taking. Soc Sci Med, 2005; 61:133–155.
29.
KerseN, BuetowS, MainousAG3rd, YoungG, CosterG, ArrollB. Physician-patient relationship and medication compliance: a primary care investigation. Ann Fam Med, 2004; 2:455–461.
30.
HaffnerSM, LehtoS, RönnemaaT, PyöräläK, LaaksoM. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 1998; 339:229–234.
31.
CarnethonMR, BiggsML, BarzilayJ, KullerLH, MozaffarianD, MukamalK, SmithNL, SiscovickD. Diabetes, coronary heart disease as risk factors for mortality in older adults. Am J Med, 2010; 123:556.e1–e9.
32.
BartnikM, RydénL, MalmbergK, OhrvikJ, PyöräläK, StandlE, FerrariR, SimoonsM, Soler-SolerJ. Euro Heart Survey Investigators: The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J, 2004; 25:1990–1997.
33.
International Expert Committee. NathanDM. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care, 2009; 32:1327–1334.
34.
SchnellO, HoffmannU, OtterW, HeinemannL, Hunger-BattefeldW, KulzerB, KlingeA, LodwigV, Amann-ZalánI, SturmD, TschöpeD, SpitzerSG, StumpfJ, LohmannT, DörrR. Die “Silent Diabetes” Studie: Oraler Glukosetoleranztest vs. HbA1c zur Neudiagnose des Diabetes bei Patienten mit KHK-Verdacht [poster P132, 46]Presented at Poster Session A, 46th Annual Meeting of the German Diabetes Society DDG, June 1–4, 2011, Leipzig, Germany.
35.
von EckardsteinA, SchulteH, AssmannG. Risk for diabetes mellitus in middle-aged Caucasian male participants of the PROCAM study: implications for the definition of impaired fasting glucose by the American Diabetes Association. J Clin Endocrinol Metab, 2000; 85:3101–3108.
36.
Cholesterol Treatment Trialists' (CTT) Collaboration:. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet, 2010; 376:1670–1681.
37.
The ACCORD Study Group: Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563–1574. Erratum in N Engl J Med, 2010; 362:1748.
38.
SorrentinoSA, BeslerC, RohrerL, MeyerM, HeinrichK, BahlmannFH, MuellerM, HorváthT, DoerriesC, HeinemannM, FlemmerS, MarkowskiA, ManesC, BahrMJ, HallerH, von EckardsteinA, DrexlerH, LandmesserU. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation, 2010; 121:110–122.
39.
DrewBG, DuffySJ, FormosaMF, NatoliAK, HenstridgeDC, PenfoldSA, ThomasWG, MukhamedovaN, de CourtenB, ForbesJM, YapFY, KayeDM, van HallG, FebbraioMA, KempBE, SviridovD, SteinbergGR, KingwellBA. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation, 2009; 119:2103–2111.
40.
von EckardsteinA, SiblerRA. Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2. Curr Opin Lipidol, 2011; 22:26–32.
41.
KhotUN, KhotMB, BajzerCT, SappSK, OhmanEM, BrenerSJ, EllisSG, LincoffAM, TopolEJ. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA, 2003; 290:898–904.
42.
RidkerPM, DanielsonE, FonsecaFA, GenestJ, GottoAMJr, KasteleinJJ, KoenigW, LibbyP, LorenzattiAJ, MacFadyenJG, NordestgaardBG, ShepherdJ, WillersonJT, GlynnRJ. JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med, 2008; 359:2195–2207.
43.
PradhanAD, EverettBM, CookNR, RifaiN, RidkerPM. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. JAMA, 2009; 302:1186–1194.
44.
GoldfineAB, FonsecaV, JablonskiKA, PyleL, StatenMA, ShoelsonSE. TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team: The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med, 2010; 152:346–357.
45.
BlankenbergS, ZellerT, SaarelaO, HavulinnaAS, KeeF, Tunstall-PedoeH, KuulasmaaK, YarnellJ, SchnabelRB, WildPS, MünzelTF, LacknerKJ, TiretL, EvansA, SalomaaV. MORGAM Project: Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation, 2010; 121:2388–2397.
YusufS, HawkenS, OunpuuS, DansT, AvezumA, LanasF, McQueenM, BudajA, PaisP, VarigosJ, LishengL. INTERHEART Study Investigators: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet, 2004; 364:937–952.
48.
TurnerRC, MillnsH, NeilHAW, StrattonIM, ManleySE, MatthewsDR, HolmanRR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)BMJ, 1998; 316:823–828.
49.
TaylorAJ, SullenbergerLE, LeeHJ, LeeJK, GraceKA. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation, 2004; 110:3512–3517.
50.
SteinEA, StroesES, SteinerG, BuckleyBM, CapponiAM, BurgessT, NiesorEJ, KallendD, KasteleinJJ. Safety and tolerability of dalcetrapib. Am J Cardiol, 2009; 104:82–91.
51.
CannonCP, ShahS, DanskyHM, DavidsonM, BrintonEA, GottoAM, StepanavageM, LiuSX, GibbonsP, AshrafTB, ZafarinoJ, MitchelY, BarterP. DEFINE Investigators: Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med, 2010; 363:2406–2415.
52.
Hofmann-La Roche. A study assessing the effect of RO4607381 on vascular function in patients with coronary heart disease (CHD) or CHD-risk equivalent patientsNCT00655538. ClinicalTrials.gov2011 May 23.
53.
Hofmann-La Roche. A study of the effect of RO4607381 on atherosclerotic plaque in patients with coronary heart diseaseNCT00655473. ClinicalTrials.gov2011 May 23.
54.
Hofmann-La Roche. A study of the effect of dalcetrapib on artherosclerotic disease in patients with coronary artery diseaseNCT01059682. ClinicalTrials.gov2011 May 23.
55.
PlassmannH, O'DohertyJ, ShivB, RangelA. Marketing actions can modulate neural representations of experienced pleasantness. Proc Natl Acad Sci U S A, 2008; 105:1050–1054.